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ABSTRACT The microbial communities inhabiting chronic infections are often com-
posed of spatially organized micrometer-sized, highly dense aggregates. It has recently
been hypothesized that aggregates are responsible for the high tolerance of chronic in-
fections to host immune functions and antimicrobial therapies. Little is currently known
regarding the mechanisms controlling aggregate formation and antimicrobial tolerance
primarily because of the lack of robust, biologically relevant experimental systems that
promote natural aggregate formation. Here, we developed an in vitro model based on
chronic Pseudomonas aeruginosa infection of the cystic ﬁbrosis (CF) lung. This model uti-
lizes a synthetic sputum medium that readily promotes the formation of P. aeruginosa
aggregates with sizes similar to those observed in human CF lung tissue. Using high-
resolution imaging, we exploited this model to elucidate the life history of P. aeruginosa
and the mechanisms that this bacterium utilizes to tolerate antimicrobials, speciﬁcally,
bacteriophage. In the early stages of growth in synthetic sputum, planktonic cells form
aggregates that increase in size over time by expansion. In later growth, migrant cells
disperse from aggregates and colonize new areas, seeding new aggregates. When
added simultaneously with phage, P. aeruginosa was readily killed and aggregates were
unable to form. When added after initial aggregate formation, phage were unable to
eliminate all of the aggregates because of exopolysaccharide production; however, seed-
ing of new aggregates by dispersed migrants was inhibited. We propose a model in
which aggregates provide a mechanism that allows P. aeruginosa to tolerate phage ther-
apy during chronic infection without the need for genetic mutation.
IMPORTANCE Bacteria in chronic infections often reside in communities composed
of micrometer-sized, highly dense aggregates. A primary challenge for studying ag-
gregates has been the lack of laboratory systems that promote natural aggregate
formation in relevant environments. Here, we developed a growth medium that
mimics chronic lung infection and promotes natural aggregate formation by the
bacterium Pseudomonas aeruginosa. High-resolution, single-cell microscopy allowed
us to characterize P. aeruginosa’s life history—seeding, aggregate formation, and dis-
persal—in this medium. Our results reveal that this bacterium readily forms aggre-
gates that release migrants to colonize new areas. We also show that aggregates al-
low P. aeruginosa to tolerate therapeutic bacteriophage addition, although this
treatment limits P. aeruginosa dissemination by targeting migrants.
Chronic bacterial infections represent a signiﬁcant health crisis throughout theworld, and the growing prevalence of antibiotic resistance in these infections has
led to increasing morbidity and mortality (1). With a lack of new antibiotics in the
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discovery pipeline, alternative therapies are needed to treat the multidrug-resistant
pathogens causing chronic infections. One such treatment is the use of the natural viral
parasites of bacteria called bacteriophage or phage. Treatment with phage was con-
sidered a promising therapeutic option in the early 20th century; however, with the
mass production of effective antibiotics after World War II, this line of research was
abandoned in all but a few countries (2).
Recently, there has been renewed interest in using phage therapy to treat
antimicrobial-resistant pathogens, and its effectiveness has been demonstrated in
animal models of septicemia and skin and lung infections (3–5). Phage exhibit the
greatest efﬁcacy when added simultaneously with bacterial cells or shortly after the
introduction of microbes into an infection site (3, 5–7). Indeed, prophylactic or rapid
treatment following infection has been shown to be effective in preventing acute lung
infection in mice; however, when treatment was delayed by as little as 2 h following
pathogen introduction, efﬁcacy decreased by almost 30% (8). These studies demon-
strate that coinoculation of phage with bacterial cells is more effective than the use of
phage to treat established infections. The reason for this decreased effect is poorly
understood, and a basic question that remains is whether phage therapy should be
limited to the early stages of an infection or whether a better understanding of
phage-bacterium interactions could be used to more effectively treat established
chronic infections.
In vivo studies utilizing phage therapy have given hints to phage-bacterium dynam-
ics, but basic details are difﬁcult to uncover in these complex, experimentally restricted
systems. For this reason, in vitro systems have been used to uncover basic aspects of
bacterial growth and resistance. Microﬂuidic devices, in particular, have been used to
study slime-enclosed communities, or bioﬁlms, which are thought to be a major
contributor to the persistence of chronic infections. This persistence has been hypoth-
esized to be due to the ability of bioﬁlm bacteria to tolerate host immune functions and
antimicrobial therapies (9, 10). However, most in vitro bioﬁlm systems lack several
important aspects of chronic infections, including the following. The number of cells
occupying these in vitro bioﬁlms can be 10- to 100-fold greater than those observed in
similar volumes in vivo (9–11). The nutritional environment used to propagate in vitro
bioﬁlms does not generally mimic those in chronic infections, although nutrient
availability has a profound impact on bioﬁlm development and activity (10, 12). The
physical environment, including attachment to plastic or glass and high-ﬂow condi-
tions, does not accurately reﬂect soft tissue and lung infections (9, 10, 13). For these
reasons, there is a need to develop in vitro systems that mimic chronic bioﬁlm
infections.
To better understand the fundamental aspects of phage-bacterium interactions, we
developed a model system that mimics chronic infection by the opportunistic patho-
gen Pseudomonas aeruginosa. P. aeruginosa causes a wide range of acute and chronic
infections but is most noted as a cause of lung and wound infections, both of which
have been proposed as viable phage therapy targets (4, 8, 14). One of the most
important lung infections caused by P. aeruginosa occurs in individuals with the genetic
disorder cystic ﬁbrosis (CF). In the CF lung, P. aeruginosa resides in the abundant mucus
secretions (here referred to as sputum) produced by individuals with CF. Previously, our
lab developed a deﬁned synthetic medium that closely mimics the nutritional compo-
sition of human CF sputum (15, 16). Further reﬁnement of this medium by the addition
of macromolecules found in CF sputum (mucin, DNA, lipids) revealed that growth of
P. aeruginosa in this second-generation medium (termed synthetic CF sputum medium
2 [SCFM2]) has genetic requirements similar to those of human sputum (17). Therefore,
SCFM2 nutritionally mimics human CF sputum and provides a relevant in vitro growth
environment for studying chronic P. aeruginosa CF infections.
In addition to the nutritional environment, the physical structure of the community
is also critical when designing in vitro models. For example, P. aeruginosa has been
shown to grow as micrometer-sized, highly dense aggregates during chronic infection
(18), and these aggregates exhibit clinically relevant phenotypes such as antimicrobial
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tolerance (1, 13, 19). In this study, we show that when grown under static conditions in
SCFM2, P. aeruginosa grows as aggregates that readily shed bacteria to colonize new
areas and seed new aggregates. Viable aggregates of volumes of 34 m3 (~34 cells) and
larger are observed following phage treatment and require exopolysaccharide for
survival. Though these aggregates display increased tolerance to phage killing, the
migrants they release are readily eliminated by phage, thus preventing dissemination
and further bacterial spread. These data support a model in which P. aeruginosa
aggregates are a primary means by which this bacterium tolerates phage therapy
during chronic infection and suggest that although phage therapy may not provide a
sterilizing effect, it might serve as a viable means to prevent the dissemination of
aggregate infections. Moreover, our high-resolution system provides a general model
for microbial ecologists to study bacterial life history following disturbances such as
antimicrobial therapy.
RESULTS
P. aeruginosa forms similar-size aggregates in synthetic sputum and CF lung
tissue. The initial goal of this study was to develop a model that recapitulates
important aspects of in vivo bacterial growth and physiology and then utilize this model
to provide insights into how microbes respond to antimicrobial therapies. The spatial
structure of microbial communities has been shown to play a signiﬁcant role in ﬁtness
(20), and recent evidence (18) suggests that P. aeruginosa grows as small (micrometer
scale), high-density aggregates in human CF infections (Fig. 1a). As these aggregates
have been proposed to be critical for P. aeruginosa tolerance to host factors and
antibiotics (13, 19), we ﬁrst assessed whether P. aeruginosa grows as aggregates in our
synthetic sputum (SCFM2). Planktonic (free-swimming) P. aeruginosa bacteria express-
ing the green ﬂuorescent protein (GFP) were added to SCFM2, mixed thoroughly to
randomly distribute them, and then added to the wells of chamber slides. At 7 and 22 h
postinoculation, confocal laser scanning microscopy (CLSM) was used to generate
three-dimensional (3D) images. Our results revealed that P. aeruginosa readily forms
aggregates in SCFM2 (Fig. 1b). To determine if aggregate sizes were similar in human
lung tissue and SCFM2, the area of P. aeruginosa aggregates was determined in human
CF lung tissue, 7-h SCFM2 aggregates, and 22-h SCFM2 aggregates. Area (rather than
volume) measurements were used because P. aeruginosa aggregates in human CF lung
tissue samples can only be examined by using thin tissue slices. A range of sizes that
showed signiﬁcant overlap for SCFM2 and human CF lung tissues were observed for
aggregates under all conditions (Fig. 1c). As observed in the CF lung, P. aeruginosa also
displayed increased resistance to the antibiotics tobramycin and polymyxin B in SCFM2
(see Fig. S1 in the supplemental material). These results reveal that, in addition to
having similar gene expression and gene ﬁtness proﬁles in SCFM2 and human CF lung
tissue (16, 17, 21), P. aeruginosa resides in aggregated groups of similar size under both
conditions and displays similar antibiotic resistance phenotypes. It is worth noting that
aggregate formation in SCFM2 is not limited to strain PAO1 but is also observed in
strain PA14 and in CF isolate SED4 (see Fig. S2d and e); it is, however, speciﬁc to SCFM2
compared to standard laboratory medium (see Fig. S2a to c).
P. aeruginosa grows through aggregate expansion and dispersal. The observa-
tion that the aggregate sizes in human CF lung tissue and synthetic CF sputum were
similar prompted further investigations of P. aeruginosa’s development in this synthetic
environment. To accomplish this, we introduced a P. aeruginosa strain expressing the
red ﬂuorescent protein mCherry into SCFM2 and calculated the total biomass at various
time points by quantifying the total red ﬂuorescent voxels in CLSM 3D images. Our
results revealed that P. aeruginosa grows readily in our static SCFM2 system (Fig. 2a),
with an average doubling time of approximately 1.3 h (see Fig. S3a), slightly longer than
that observed previously when it was grown with vigorous shaking in synthetic sputum
medium (16, 17). To determine if the increase in biomass observed was due to an
increased aggregate size (i.e., volume) or an increased number of aggregates, we
measured the aggregate volume and quantiﬁed the number of aggregates at each time
Phage Inhibit Pathogen Aggregate Formation and Dissemination ®
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point. The average aggregate volume increased ~3-fold (Fig. 2b; see Fig. S3b) and the
number of aggregates increased ~2-fold (Fig. 2c) between 4 and 7 h, while the biomass
increased ~8-fold (Fig. 2a).
Surprisingly, the average aggregate volume remained the same at 7 and 22 h
(Fig. 2b) although the biomass increased by ~4-fold. This increase in biomass could be
explained by the fact that the number of aggregates also increased by ~4-fold during
this time period (Fig. 2c). These data indicate that early P. aeruginosa growth (4 to 7 h)
is accomplished through increased aggregate volume and increased aggregate num-
bers, while later stages of growth (7 to 22 h) are accomplished via the formation of new
aggregates. After 45 h, the total biomass decreases, as does the average aggregate
volume, suggesting that cells either die or become smaller (see Fig. S3). What appears
to be occurring is a dynamic process in which established aggregates increase in
volume up to a maximum size of ~1,000 m3 (~1,000 rod-shaped cells with a size of 0.8
by 2 m, see Fig. S3c), while the average size is maintained much smaller at ~85 m3
because new aggregates are being continually formed in ever larger numbers, offset-
FIG 1 P. aeruginosa aggregate sizes are similar in human CF tissue and SCFM2. (a) Micrograph of a
P. aeruginosa aggregate in an explanted human CF lung tissue section. P. aeruginosa was labeled by FISH.
P. aeruginosa cells are red, and polymorphonuclear leukocytes are blue. (b) Confocal micrograph of a
GFP-expressing P. aeruginosa aggregate in SCFM2 at 22 h postinoculation. (c) Cross-sectional area of
P. aeruginosa aggregates from explanted CF lung tissue and P. aeruginosa aggregates grown for 7 and
22 h in SCFM2. Each symbol represents an aggregate, and the median is indicated by a broken red line.
Measurements were accomplished by manually outlining aggregates, and the area within the outline
was calculated with Fiji image analysis software. For these measurements, aggregates were assumed to
be entirely ﬁlled with cells.
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ting the continued growth of the large aggregates. The process may resemble the
demographic phenomenon of a stable age distribution.
Many P. aeruginosa aggregates survive phage treatment On the basis of the
observation that P. aeruginosa forms similar-size aggregates (Fig. 1) and displays similar
physiology in SCFM2 and the CF lung (see Fig. S1) (15–17), we next examined the utility
of this model for assessment of the efﬁcacy of phage therapeutics. The goal was to
provide insights into why phage therapy shows limited efﬁcacy when used to treat
FIG 2 P. aeruginosa growth in SCFM2 occurs via aggregate expansion and the formation of new
aggregates. (a) Growth of P. aeruginosa in SCFM2 determined by quantiﬁcation of the total biomass. The
biomass of P. aeruginosa expressing mCherry was quantiﬁed as the number of red ﬂuorescent voxels. A
heterogeneity test was signiﬁcant by ANOVA (F2,9 104.5, P 0.0001). An asterisk denotes a statistically
signiﬁcant difference by two-tailed t test for comparison of 4- and 7-h data [t(6)  3.298, P  0.0457] and
comparison of 7- and 22-h data [t(6)  6.533, P  0.0007]. (b) Average P. aeruginosa aggregate volume
in SCFM2. To measure the average P. aeruginosa aggregate volume in SCFM2, the total volume of red
ﬂuorescent voxels within an aggregate was quantiﬁed. These measurements differ from those in Fig. 1c,
as the high-resolution 3D images used in this analysis allow the precise quantiﬁcation of cells without the
assumption that aggregates are entirely ﬁlled with cells. A heterogeneity test was marginally signiﬁcant
by ANOVA (F2,9 4.139, P 0.0531). An asterisk denotes a statistically signiﬁcant difference by two-tailed
t test [t(6)  2.568, P  0.04]. (c) Total number of P. aeruginosa aggregates in SCFM2. Aggregates were
deﬁned as cell clusters of5.0 m3, and all of the aggregates within each image with dimensions of 135
by 135 by 60 mwere counted. A heterogeneity test was signiﬁcant by ANOVA (F2,9 10.75, P 0.0041).
An asterisk denotes a statistically signiﬁcant difference by two-tailed t test for comparison of 4- and 7-h
data [t(6)  7.261, P  0.0014] and comparison of 7- and 22-h data [t(6)  2.854, P  0.0290]. The bars
in all of the panels represent the average  the standard error of the mean of four replicates.
Phage Inhibit Pathogen Aggregate Formation and Dissemination ®
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established infections while exhibiting high efﬁcacy when used prophylactically (4,7,8).
For this study, we used a cocktail of two lytic phage that have been proposed to utilize
different receptors and were previously used in phage therapy studies (14). Phage were
added at a 2:1 ratio with bacteria, and this level of phage was sufﬁcient to sterilize a
P. aeruginosa planktonic culture grown in laboratory medium within 18 h (~7-log
reduction, with cell elimination to the limit of detection; see Fig. S5a). As most phage
therapy studies have shown maximum effectiveness both in vitro and in vivo when
phage are coinoculated with bacteria, we initiated our studies by adding the phage
cocktail simultaneously with P. aeruginosa into SCFM2 and examining the biomass for
18 h. Coinoculation with phage resulted in an ~100-fold decrease in P. aeruginosa
biomass after 18 h (see Fig. S5b), further supporting the effectiveness of phage as
prophylactic therapeutics.
To examine the impact of phage addition on microbial communities growing as
aggregates, we allowed P. aeruginosa to form aggregates in synthetic medium for 4 h
(4 h, Fig. 3a) and then treated these communities with the phage cocktail. Phage had
no signiﬁcant impact on P. aeruginosa biomass at 3 h after phage addition (7 h, Fig. 3a),
while there was a signiﬁcant decrease in the biomass of phage-treated communities
18 h after phage addition (22 h, Fig. 3a). However, unlike the coinoculation experiments
(see Fig. S5B), communities allowed to develop for 4 h, and therefore containing
P. aeruginosa aggregates, retained high levels of viable biomass (~50% of untreated
communities, Fig. 3a; see Fig. S5c), suggesting that these communities are more
recalcitrant to phage treatment. Examination of aggregate volumes revealed that,
similar to biomass (Fig. 3a), phage treatment had no signiﬁcant impact on the average
volume of individual aggregates 3 h after phage addition (7 h, Fig. 3b). Indeed, average
aggregate volumes increased ~3-fold between 4 and 7 h under both phage-treated and
untreated conditions (Fig. 3b), indicating that the ~4-fold increase in biomass observed
during this time was, in part, due to an increased volume of individual aggregates.
Aggregate volume and number did show a signiﬁcant decline at the latest time point
in phage-treated cultures (22 h, Fig. 3b and c), indicating that while aggregates are
clearly more tolerant to phage, they do potentially display some susceptibility after
longer exposure times. These results reveal that preincubation of P. aeruginosa for 4 h
in SCFM2 signiﬁcantly enhances tolerance to phage treatment, and a signiﬁcant portion
of the increased biomass observed following phage treatment is due to increased
aggregate volume. Of note, treatment of aggregates with individual phage did not
cause a signiﬁcant reduction in biomass after 22 h, indicating that the addition of both
phage is required (see Fig. S4).
P. aeruginosa exopolysaccharides provide protection against phage. In vitro
bioﬁlm studies have shown that bacterial exopolysaccharides can, in some but not all
cases, provide protection against phage (22–24); thus, we next examined whether
P. aeruginosa exopolysaccharides protected aggregates from phage-mediated killing.
P. aeruginosa PAO1 has the capacity to produce at least three extracellular polysaccha-
rides; alginate, Pel, and Psl. Since alginate is not produced by strain PAO1 in bioﬁlms
(25), we focused on Pel and Psl in these experiments. We compared the aggregate
formation and phage tolerance of wild-type P. aeruginosa to those of an isogenic
P. aeruginosamutant that cannot produce Pel and Psl. Elimination of Pel and Psl did not
impact the ability of P. aeruginosa to produce aggregates (Fig. 4a), and the average size
of these aggregates was, on average, larger than that of those formed by the wild type
(although the difference was not statistically signiﬁcant, P 0.18). However, aggregates
formed by the Pel/Psl mutant were signiﬁcantly more susceptible to killing by phage
than those formed by exopolysaccharide-producing wild-type P. aeruginosa, as deter-
mined by calculation of the total biomasses of untreated and phage-treated cultures
(Fig. 4b). Similar to the Pel/Psl mutant, P. aeruginosa mutants unable to produce
individual polysaccharides formed aggregates; however, these mutants did not display
increased susceptibility to phage killing (see Fig. S6). These data indicate that PAO1
Darch et al. ®
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FIG 3 Phage have a minimal impact on preformed P. aeruginosa aggregates but prevent the formation
of new aggregates. (a) Average P. aeruginosa growth (total biomass) in SCFM2 in the presence and
absence of phage. P. aeruginosa was allowed to form aggregates for 4 h before phage addition, and the
biomass was calculated 3 and 18 h after phage addition. A heterogeneity test was signiﬁcant, as
determined by ANOVA (F2,9  1.3, P  0.0503). An asterisk denotes a statistically signiﬁcant difference
by two-tailed t test [t(6)  3.633, P  0.0170]. (b) P. aeruginosa average aggregate volumes in SCFM2 in
the presence and absence of phage. P. aeruginosa was allowed to form aggregates for 4 h before phage
addition, and the aggregate volume was calculated 3 and 18 h after phage addition. A heterogeneity test
was signiﬁcant, as determined by ANOVA (F2,9  4.143, P  0.053). An asterisk denotes a statistically
signiﬁcant difference by two-tailed t test [t(6)  29.21, P  0.0001]. (c) Total numbers of P. aeruginosa
aggregates in SCFM2 in the presence and absence of phage. Aggregates were deﬁned as cell clusters
of5.0 m3, and all of the aggregates within each image with dimensions of 135 by 135 by 60 m were
counted. A heterogeneity test was signiﬁcant by ANOVA (F2,9  34.208, P  0.0004). An asterisk
denotes a statistically signiﬁcant difference between groups at 22 h by two-tailed t test [t(6)  3.75, P 
0.0095]. The bars in all of the panels represent the average  the standard error of the mean of four
replicates
Phage Inhibit Pathogen Aggregate Formation and Dissemination ®
March/April 2017 Volume 8 Issue 2 e00240-17 mbio.asm.org 7
 
m
bio.asm
.org
 o
n
 D
ecem
ber 27, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
exopolysaccharides are not required for aggregate formation in SCFM2 and that Pel
and Psl collectively protect aggregates against phage.
Phage target bacterial migrants. Why does the biomass of P. aeruginosa aggre-
gate communities increase during the ﬁrst 3 h following phage treatment but not the
next 18 h (Fig. 3a)? Since early bacterial growth (4 to 7 h, Fig. 2) is accomplished
through increases in aggregate volume and aggregate numbers, while later growth (7
to 22 h, Fig. 2) is accomplished via the formation of new aggregates, we hypothesized
that phage inhibit the formation of new aggregates by targeting migrant bacteria that
disperse from existing aggregates. To test this hypothesis, we used CLSM to assess
dispersed and aggregated biomasses in the presence and absence of phage. We
predicted that if phage target bacterial migrants, fewer dispersed cells would be
observed in phage-treated samples than in untreated samples. For these experiments,
dispersed biomass was considered to be volumes of 5 m3, while aggregated
groups were volumes of 5 m3. These values were chosen on the basis of the idea
that P. aeruginosa could be motile and disperse as individual cells or small groups
of 5 m3 (~5 cells) but not larger groups. As in previous experiments, P. aeruginosa
was ﬁrst allowed to form aggregates for 4 h in SCFM2 before phage addition, and
CLSM was performed every 30 min for 15 h to provide a reﬁned assessment of
aggregate formation. In the absence of phage, dispersed cells were observed
throughout the experiment (Fig. 5a), although the amount of dispersed biomass
differed between replicates (see Fig. S7). There were also several time points when
FIG 4 P. aeruginosa Pel and Psl exopolysaccharides are not required for aggregate formation but provide
protection from phage killing. (a) Average aggregate volumes of wild-type P. aeruginosa and P. aerugi-
nosa ΔpelΔpsl in SCFM2 in the presence and absence of phage. P. aeruginosa was allowed to form
aggregates for 4 h in SCFM2 before phage addition, and the aggregate volume was assessed 18 h later.
Bars represent the average  the standard error of the mean of four replicates. Aggregate volumes were
not statistically signiﬁcantly different by ANOVA (F1,6 2.28, P 0.1819). (b) Wild-type P. aeruginosa and
P. aeruginosa ΔpelΔpsl biomasses following phage treatment. Wild-type P. aeruginosa and P. aeruginosa
ΔpelΔpsl were allowed to form aggregates for 4 h in SCFM2 before phage addition, and their biomasses
were assessed 18 h later. Bars represent the average fraction of biomass present in phage-treated and
untreated samples. Error bars show the standard error of the mean of four replicates. An asterisk denotes
a statistically signiﬁcant difference between wild-type P. aeruginosa and P. aeruginosa ΔpelΔpsl, as
determined by a two-tailed t test [t(12)  2.4656, P  0.0149].
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dispersed biomass increased sharply within a 1-h period, often 100-fold (Fig. 5a;
see Fig. S7 and Video S1). In contrast, the presence of phage signiﬁcantly decreased
the levels of dispersed cells and no sharp increases in dispersal were observed;
however, small numbers of dispersed cells were always observed in these cultures
(Fig. 5a; see Fig. S7 and Video S2). Collectively, these results suggest that phage
impact P. aeruginosa colonization of new areas by decreasing the number of
dispersed cells.
Phage reduce aggregate dispersal. To further test the hypothesis that phage
target bacterial migrants, we developed an aggregate dispersal assay to directly assess
the impact of phage treatment on P. aeruginosa dispersal. This assay begins by forming
P. aeruginosa aggregates for 4 h, followed by the addition of sterile SCFM2 on top of
the SCFM2 containing aggregates. This assay measures dispersal by examining the
appearance of P. aeruginosa biomass in the overlying uninoculated SCFM2 after 6 h. In
the absence of phage, P. aeruginosa was readily observed in the uninoculated SCFM2,
as both single cells (6% of the dispersed biomass, deﬁned as sizes of 0.5 to 3 m3) and
as larger aggregates; however, addition of phage signiﬁcantly reduced dispersal
(Fig. 5b). As expected, P. aeruginosa was observed in the bottom SCFM2 layer following
phage treatment (see Fig. S8a) and most of this biomass was in the form of aggregates
(Fig. S8b), indicating that the lack of dispersal was not due to phage-mediated
aggregate killing. These data reveal that P. aeruginosa migrates and colonizes new sites
in SCFM2 and does this, at least in part, as single cells. In addition, these results indicate
that while phage do not eliminate all of the established aggregates, they do prevent
P. aeruginosa dispersal.
FIG 5 Phage reduce bacterial migrant numbers and prevent P. aeruginosa dispersal. (a) Dispersed
P. aeruginosa biomasses during growth in SCFM2 in the presence () and absence () of phage.
P. aeruginosa was allowed to form aggregates for 4 h in SCFM2 before phage addition, and the dispersed
biomass was assessed every 30 min for 15 h. Dispersed biomass was deﬁned as individual cell clusters
of5.0 m3, which corresponds to about one to ﬁve bacteria. Data from a single replicate are presented
for clarity. Three additional replicates are shown in Fig. S7. (b) Dispersal of P. aeruginosa in SCFM2.
P. aeruginosa was allowed to form aggregates for 4 h in SCFM2 and then overlaid with sterile SCFM2
(untreated) or SCFM2 containing phage (treated). After 6 h, the amount of dispersed biomass in the
upper SCFM2 layer was determined as the number of red ﬂuorescent voxels and is represented as the
mean biomass  the standard error of the mean of four replicates. Representative micrographs of
dispersed biomass are shown above each bar. Scale bar is 20 m. An asterisk denotes a statistically
signiﬁcant difference between untreated and treated samples, as determined by a two-tailed t test [t(6)
2.5, P  0.044].
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DISCUSSION
The inability to combat chronic bacterial infections with modern therapeutics
remains a signiﬁcant problem throughout the world. While it was long ago proposed
that bacteria exist as bioﬁlms in chronic infections, it is now clear that in chronic
wounds and CF sputum, they grow as micrometer scale, highly dense aggregates (10,
13, 18, 26). While the biology of bacterial aggregates is poorly understood, they do
display characteristic phenotypes, including enhanced antibiotic tolerance and resil-
ience to host immune factors, that have been observed in conventional in vitro bioﬁlms
(19, 27–29). One of the primary challenges to studying aggregates is the lack of robust,
biologically relevant experimental systems for creating them. Here, we show that
P. aeruginosa forms aggregates readily in a synthetic CF sputum medium that chemi-
cally mimics human CF sputum (Fig. 1). This medium contains high levels of mucin,
lipid, and DNA, and these components appear to be key to aggregate formation, as
synthetic sputum without these components does not promote aggregation (15, 16).
However, it should be noted that P. aeruginosa is not restricted to aggregate growth in
SCFM2, as single cells and small groups of cells are observed throughout growth
(Fig. 5a; see Fig. S7). Indeed, while there was variability in the timing and magnitude,
there are clear instances in which the number of single cells and small groups of cells
increased dramatically (Fig. 5a; see Fig. S7). These data support a model of aggregate
formation in which planktonic cells form aggregates that release migrants that travel to
and form aggregates in uncolonized areas. Of course, while we cannot eliminate the
possibility that aggregates are formed by other mechanisms such as splitting of existing
aggregates, our data provide strong evidence that seeding of new aggregates by
migrants is a critical mechanism for bacterial spread in our model. It is also important
to point out that the use of a non-CF-adapted P. aeruginosa strain for these studies was
intended to mimic the initial stages of sputum colonization. Future studies will examine
the life history of CF-adapted strains or more diverse communities.
Interestingly, aggregate formation in SCFM2 does not require the P. aeruginosa
exopolysaccharides Pel and Psl (Fig. 4a). Pel and Psl have both been shown to be critical
for bioﬁlm formation in vitro, aiding surface attachment and maintaining bioﬁlm
structural integrity (30); however, those studies have generally examined bioﬁlm for-
mation on glass surfaces in ﬂowing systems with laboratory medium as the nutritional
source. Thus, it may not be surprising that Pel and Psl are not important for aggregate
formation in viscous, static SCFM2. We speculate that polymers such as mucin and DNA
in the synthetic medium may provide structural scaffolds for aggregate formation, thus
eliminating the need for exopolysaccharide production. However, these components
were not sufﬁcient for protection against phage, as Pel and Psl were critical determi-
nants of aggregate tolerance (Fig. 4b). The reduction in exopolysaccharide mutant
biomass after treatment with phage indicates that the mechanism of aggregate
tolerance is, at least in part, due to exopolysaccharide production. Exopolysaccharides
have been shown to be important for phage tolerance in some, but not all, bacteria
(22–24), although these studies have not focused on aggregates. Another possibility is
that the presence of Pel and Psl impacts the accessibility or level of the phage receptor.
Collectively, these results suggest that phage containing exopolysaccharide-degrading
enzymes or other strategies targeting exopolysaccharide biosynthesis or stability may
be a viable means of enhancing phage effectiveness against bacterial aggregates. Such
strategies using glycoside hydrolases to target P. aeruginosa exopolysaccharides have
shown promise in enhancing the susceptibility of bioﬁlms to neutrophil killing (31).
A large number of phage therapy studies show high efﬁcacy when phage are
administered prophylactically with low-density planktonic bacteria; however, treatment
of established infections often results in a minimal impact on bacterial numbers and
disease outcomes (4, 8, 32). High-density bioﬁlm growth has been hypothesized as a
mechanism of antimicrobial protection in established infection, and recent evidence
supporting this hypothesis shows that social interactions during high-density growth
are key to bacterial phage tolerance (33). While it is clear that bacteria do not grow as
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traditional “mushroom” bioﬁlms in many infections, including CF (13, 18), our discovery
that aggregates with volumes of 34 m3 are present following phage treatment and
even grow in the presence of phage (Fig. 3) provides strong experimental evidence that
aggregates must reach a critical mass to tolerate phage. In addition to protection by
exopolysaccharides, the concept of a “critical” aggregate size provides new insights into
the mechanisms microbes use to evade phage killing. It could be argued that the
resistance of aggregates to phage may be due to the increase in biomass that occurs
during aggregate formation in our experimental system. However, we do not favor this
idea since the exopolysaccharide mutant, which increases similarly in biomass, is highly
susceptible to phage (Fig. 4b). Thus, the levels of phage utilized in our experimental
design are sufﬁcient to reduce aggregate population numbers in the time frame of our
experiment. Collectively, our results suggest that phage therapy will likely have limited
utility in eliminating bacterial infections caused by aggregates. Nevertheless, the
observation that treatment with phage reduces the number of bacterial migrants and
prevents the colonization of new areas (Fig. 5) suggests a potential role for these
treatments in preventing the spread of aggregate infections.
On the basis of the results of this study, we propose a model of the life history of
P. aeruginosa in synthetic sputum (Fig. 6) that initiates with planktonic cells establishing
aggregates within 4 h that increase in size at 7 h. Subsequent growth of the community
is primarily mediated by the release of migrants from aggregates that travel to
uncolonized regions and develop into aggregates. The effect of phage treatment on
the bacterial community is dependent on the developmental stage, as phage can
largely prevent initial aggregate formation by planktonic cells and the formation of new
aggregates by migrants while having less of an effect on established aggregates (Fig. 6).
In retrospect, targeting of P. aeruginosa migrants is not a surprise, as P. aeruginosa
migration is accomplished, at least in part, by single planktonic cells that should be
susceptible to phage attack (Fig. 5a). An alternative possibility is that phage addition
simply causes P. aeruginosa aggregates not to release migrants. We ﬁnd this unlikely,
given the fact that single cell migrants were observed in both our phage-treated
aggregate dispersal experiment (Fig. 5b) and our time-lapse experiment (Fig. 5a; see
Video S2). Ultimately, our results provide new insights into the life history of P. aerugi-
nosa during the colonization of synthetic sputum, as well as a robust model for
FIG 6 Model of P. aeruginosa life history and phage susceptibility in SCFM2. Upon entering synthetic
sputum, planktonic P. aeruginosa (shown in green on the left side) readily forms aggregates (shown in
orange) within 4 h that increase in volume by 7 h. At 7 h, planktonic migrants are released from
aggregates (shown in green on the right side) that move to unoccupied areas and ultimately seed new
aggregates. Phage block planktonic P. aeruginosa from forming aggregates (inhibit aggregate formation)
and dispersed cells from forming new aggregates (inhibit dissemination).
Phage Inhibit Pathogen Aggregate Formation and Dissemination ®
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studying the mechanisms used by P. aeruginosa to tolerate environmental insults such
as phage therapy.
MATERIALS AND METHODS
Strains and media used. Experiments were performed with wild-type P. aeruginosa strain PAO1
carrying either GFP-expressing plasmid pMRP9-1 (34) (Fig. 1b) or mCherry-expressing plasmid pGJB5 (all
other ﬁgures) (28). Antibiotic resistance studies were performed with PAO1 carrying the luminescence
reporter plasmid pQF50-lux (35). To determine if aggregate formation was strain speciﬁc, P. aeruginosa
strain PA14 and LESB58 clinical isolate SED4 (36) carrying pMRP9-1 (34) were used. Studies examining the
importance of exopolysaccharides for aggregate formation and phage tolerance were performed with
P. aeruginosa PAO1 Δpel Δpsl and PAO1 Δpsl (25) containing pGJB5 (28) and PAO1 Δpel and PAO1 ΔalgD
(25) containing pMRP9-1 (34). Overnight cultures were grown in tryptic soy broth (TSB) at 37°C with
shaking at 200 rpm. All washing steps were performed with 1 phosphate-buffered saline (PBS), pH 7.0.
Aggregate studies were performed with SCFM2 (17).
Aggregate formation in SCFM2. P. aeruginosa carrying pMRP9-1 or pGJB5 was grown overnight in
TSB. Cells were washed twice and resuspended in PBS. The optical density at 600 nm (OD600) was
measured with a spectrophotometer, and washed bacterial cultures were inoculated into SCFM2 at an
OD600 of 0.05 (~107 CFU/ml). Cultures were vortexed for 5 to 10 s to disperse bacterial cells in SCFM2. Five
hundred microliters of inoculated SCFM2 was then transferred into each well of four-well microchamber
slides (Lab-Tek; Nunc) and incubated under static conditions at 37°C.
Aggregate formation in TSB and MHB. Experiments were prepared as described in the previous
paragraph, but cells were inoculated into either Mueller-Hinton broth (MHB) or TSB and incubated under
static conditions at 37°C.
MIC assay. The antibiotics tobramycin sulfate and polymyxin B were prepared in stock solutions of
10 mg/ml and diluted to the required concentrations in sterile distilled water. Two hundred microliters
of SCFM2 or MHB containing antibiotic was added to the appropriate wells of a 96-well microtiter plate
and serially diluted 2-fold across adjacent wells of the plate into 100 l of appropriate medium,
producing a concentration range of 2.5 to 0.005 mg/ml. One hundred microliters of washed P. aeruginosa
PAO1 carrying plasmid pQF50-lux was adjusted to a standardized OD600 of 0.05 in either medium. One
hundred microliters of each isolate was then added to each appropriate well. Suitable negative controls
containing no antimicrobial and isolate-free wells were included on every microtiter plate. Cultures were
incubated statically for 60 min, after which luminescence was measured with a Luminoskan Ascent
microplate luminometer as a proxy for cell viability.
Phage treatment. Two bacteriophage belonging to Pseudomonas bacteriophage families NP3 (ATCC
12175-B1) and PA2 (ATCC 14203-B1) were used in this study (14). Phage treatment was applied as a
cocktail containing equal amounts of each phage to SCFM2 containing P. aeruginosa carrying pGJB5 to
recapitulate prophylactic therapy or treatment of an established infection. For prophylactic treatment,
immediately following the addition of SCFM2 inoculated with P. aeruginosa to the microchamber well,
the phage cocktail was added at a ratio of 2:1 (phage to bacterial cells) to the center top of SCFM2 and
agitated slightly. Cultures were then imaged by CLSM at 2, 6, and 18 h posttreatment. For the treatment
of an established infection, P. aeruginosa aggregates were allowed to develop for 4 h in a microchamber
well containing SCFM2, followed by phage addition as described above for prophylactic treatment. The
volume of phage needed to maintain a 2:1 ratio of phage to bacterial cells was calculated by using
the known total biomass of untreated cultures at 4 h (Fig. 2a). Cultures were imaged by CLSM at 4,
7, and 22 h after bacterial inoculation. All phage-treated cultures were compared with untreated
controls. To assess the viability of phage-treated cultures (see Fig. S5c), samples were removed,
serially diluted, plated onto TSB agar plates, and incubated at 37°C for 24 h to calculate the number
of CFU per milliliter.
Exopolysaccharide mutant aggregate formation and dynamics in SCFM2. Exopolysaccharide
studies were performed with P. aeruginosa PAO1 Δpel Δpsl and PAO1 Δpsl (25) containing pGJB5 (28) and
PAO1 Δpel and PAO1 ΔalgD (25) containing pMRP9-1 (34). Experiments were performed identically to the
established-infection protocol already described. Cultures were imaged by CLSM 22 h after bacterial
inoculation. All mutant studies were compared with untreated controls that were prepared identically to
samples treated with phage.
Dispersal assay. P. aeruginosa carrying pGJB5 was diluted to an OD600 of 0.05 in 250 l of SCFM2
and added to microchamber wells. Aggregates were allowed to develop for 4 h at 37°C. After 4 h, 250 l
of fresh prewarmed (to 37°C) SCFM2 without bacterial cells was then gently pipetted on top of the
SCFM2 containing preformed aggregates. Cultures were incubated statically at 37°C for a further 6 h
and then imaged by CLSM. Imaris image analysis software was used to detect dispersed biomass in
the initially uninoculated SCFM2 (this area corresponds to 60 to 100 m above the base of the
coverslip).
Imaging aggregates. All images were acquired with Zeiss LSM 700 and LSM 880 confocal laser
scanning microscopes utilizing Zen image capture software. Bacterial cells were visualized via mCherry
with an excitation wavelength of 587 nm and an emission wavelength of 610 nm or via GFP with an
excitation wavelength of 488 nm and an emission wavelength of 509 nm with a 63 oil immersion
objective. SCFM2 images were acquired by producing 512- by 512-pixel (0.26- by 0.26-m pixels) 8-bit
z-stack images that were 60 and 100 m from the base of the coverslip for phage-treated/untreated
experiments (Fig. 1 to 5) and the dispersal assay (Fig. 5b), respectively. The total volumes of the 60- and
100-m z-stack images were 1,093.5 and 1,822.5 mm3, respectively. Control images of uninoculated
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SCFM2 were acquired by using identical settings to determine the background ﬂuorescence for image
analysis.
Image analysis. All imaging was performed with identical image capture settings. To determine the
background ﬂuorescence in SCFM2, a histogram of detected mCherry ﬂuorescence was produced in
Imaris v 8.3.1 (Bitplane) for uninoculated SCFM2, and the average of the three highest voxel values was
determined as the background ﬂuorescence. Averaging across all of the control images, this value was
calculated as 81 voxels. This value was then subtracted from all experimental images with Imaris. The
aggregate areas of P. aeruginosa from CF lung tissue that were used to calculate the aggregate
cross-sectional area are from reference 18. For this study, a total of 61 peptide nucleic acid ﬂuorescence
in situ hybridization (FISH)-treated bioﬁlms taken from 17 tissue specimens from three pairs of CF lungs
were imaged. To calculate the 2D cross-sectional area of aggregates in SCFM2 from 3D confocal images,
a random-number generator was used to choose three individual slices between 10 and 50 m from the
base of the coverslip at 7 and 22 h after P. aeruginosa inoculation. With Fiji image analysis software v
2.0.0, the background ﬂuorescence was subtracted from the images. Borders were then drawn around
visible aggregates with Fiji, and the analyze particles function was used to calculate individual cross-
sectional areas. Aggregate sizes in SCFM2 were calculated from three biological replicate SCFM2 cultures
with three slices from each to calculate the cross-sectional area of 40 aggregates per culture (120
aggregates in total).
Calculation of aggregate dynamics in SCFM2. For aggregate studies in SCFM2, isosurfaces were
produced for all remaining voxels after background subtraction with the surpass module in Imaris. To
detect individual aggregates, the split objects option in Imaris was enabled and aggregates were deﬁned
as objects with volumes of 5 m3. The total biomass (all voxels detected), average aggregate volume,
number of aggregates, and the z position were calculated within the vantage module in Imaris.
Calculation of dispersed biomass in time-lapse experiments: To calculate the total dispersed biomass
over time, isosurfaces were created as described above but from 3D CLSM stacks collected at 30-min
intervals for 15 h. Detected aggregate isosurfaces were then ordered by volume. Objects that were 0.5
and5.0 m3 were categorized as dispersed biomass, and objects that were5.0 m3 were categorized
as aggregated biomass. The total dispersed biomass was calculated as the sum of all of the dispersed
objects in both untreated and treated cultures. For the dispersal assay, the ability of P. aeruginosa
aggregates to colonize uninoculated SCFM2 was determined by calculating the total biomass of
aggregates between 60 and 100 m above the coverslip. Isosurfaces were created as described above
to detect aggregates. All image data were exported into Microsoft Excel 2016, and graphs were
generated with GraphPad Prism 7.
Phage treatment of planktonic cultures. P. aeruginosa carrying pGJB5 (28) was grown overnight in
TSB at 37°C while shaking at 200 rpm. Cells were washed two times with PBS (pH 7.0). The OD600 was
measured with a spectrophotometer, and washed bacterial cultures were inoculated into TSB at an OD600
of 0.05 (~107 CFU/ml). Phage were added simultaneously with bacterial cells at a 2:1 phage-to-bacterium
ratio. Cultures were vortexed for 5 to 10 s and incubated at 37°C with shaking at 200 rpm for 18 h. A 50-l
sample was then serially diluted and plated on TSB agar plates, and the number of CFU per milliliter was
calculated. Phage-treated cultures were compared with untreated controls. Experiments were performed
in triplicate.
Statistical analysis. Statistical tests performed were by analysis of variance (ANOVA), by two-tailed
t test, randomization test, or by linear regression as stated in the ﬁgure legends. t, F, and P values for each
test, as well as the degrees of freedom, are stated in each individual ﬁgure legend.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00240-17.
VIDEO S1, AVI ﬁle, 7.9 MB.
VIDEO S2, AVI ﬁle, 4.4 MB.
FIG S1, TIF ﬁle, 0.2 MB.
FIG S2, TIF ﬁle, 1 MB.
FIG S3, TIF ﬁle, 0.3 MB.
FIG S4, TIF ﬁle, 0.2 MB.
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